What is Von Willebrand disease?
Von Willebrand disease (VWD) is the most common inherited bleeding disorder, caused by deficiency or dysfunction of von Willebrand factor, a protein essential for blood clotting. While up to 1% of the population may carry genetic variants associated with VWD, symptomatic disease requiring medical attention affects far fewer people. The condition primarily causes excessive bleeding from mucous membranes, heavy menstrual periods, and easy bruising. Despite being a lifelong condition, most people with VWD can lead normal lives with proper diagnosis and management.
Key statistics
| Prevalence | Up to 1% carry variants; symptomatic disease much rarer (0.01-0.1%) |
| Inheritance | Mostly autosomal dominant; severe forms autosomal recessive |
| Age of onset | Symptoms often present from childhood or adolescence |
| Gender distribution | Equal genetic risk; females more likely diagnosed due to menorrhagia |
Symptoms
Common symptoms: Mucocutaneous bleeding, menorrhagia, easy bruising, nosebleeds, gum bleeding, excessive bleeding after dental procedures or surgery.
Early symptoms often include frequent nosebleeds in childhood, easy bruising from minor trauma, and prolonged bleeding from small cuts. Many children experience bleeding after losing teeth that requires medical attention.
Common manifestations in adolescents and adults include heavy menstrual periods that may require frequent pad or tampon changes, bleeding that lasts longer than seven days, or causes anemia. Excessive bleeding during dental work, minor surgeries, or childbirth is characteristic.
Serious symptoms are rare but can include gastrointestinal bleeding, particularly in older adults, and life-threatening hemorrhage following major surgery or trauma. Some patients experience joint bleeding similar to hemophilia, especially in the most severe form (type 3 VWD).
Causes and risk factors
Von Willebrand disease is caused by mutations in the VWF gene, which provides instructions for making von Willebrand factor protein. This protein helps blood platelets stick together and adhere to blood vessel walls during clot formation.
Most cases follow an autosomal dominant inheritance pattern, meaning only one copy of the altered gene is needed to cause symptoms. However, the most severe form (type 3) is autosomal recessive, requiring two copies of mutated genes.
Risk factors include family history of bleeding disorders, personal history of excessive bleeding, and certain blood types (type O blood is associated with lower von Willebrand factor levels). Some acquired conditions can temporarily worsen bleeding symptoms, including certain medications, thyroid disorders, and some autoimmune conditions.
Prevention
As a genetic condition, Von Willebrand disease cannot be prevented. However, genetic counseling and testing can help families understand inheritance risks. Carrier testing is available for family members of affected individuals, though many carriers may have mild or no symptoms.
Preconception counseling is recommended for prospective parents with VWD to discuss inheritance risks and pregnancy management. Prenatal testing is possible but rarely necessary since most forms of VWD are compatible with normal life when properly managed.
Avoiding medications that impair platelet function, such as aspirin and certain anti-inflammatory drugs, can help prevent bleeding complications in diagnosed individuals.
Complications
Without proper diagnosis and management, Von Willebrand disease can lead to iron deficiency anemia from chronic bleeding, particularly in women with heavy menstrual periods. Severe bleeding episodes may require emergency medical intervention and blood transfusions.
Dental procedures, surgeries, and childbirth pose increased bleeding risks without proper preparation. Some patients develop joint problems if repeated bleeding into joints occurs, though this is more common in severe type 3 disease.
Social and psychological impacts can be significant, particularly for women whose menorrhagia affects daily activities, work, and relationships. Delayed diagnosis often leads to years of symptoms before appropriate treatment begins.
Diagnosis
Diagnosis typically begins with a detailed bleeding history using standardized questionnaires to assess bleeding severity. Initial laboratory tests include complete blood count, prothrombin time, activated partial thromboplastin time, and platelet function studies.
Specific tests for VWD include von Willebrand factor antigen, von Willebrand factor activity (ristocetin cofactor activity or GP1bM), and factor VIII activity levels. These tests may need to be repeated since von Willebrand factor levels can fluctuate due to stress, exercise, medications, and hormonal changes.
Advanced testing includes von Willebrand factor multimer analysis to determine VWD subtype, and genetic testing of the VWF gene, particularly for family screening or when considering pregnancy. Platelet aggregation studies and specialized tests like desmopressin challenge testing may be performed in specialized centers.
Treatment
Treatment depends on VWD type and bleeding severity. Desmopressin (DDAVP) is first-line therapy for many patients with type 1 VWD, temporarily increasing von Willebrand factor and factor VIII levels. It can be given as nasal spray, injection, or tablets.
For patients who don’t respond to desmopressin or have more severe disease, von Willebrand factor concentrates provide direct replacement therapy. These plasma-derived products contain both von Willebrand factor and factor VIII.
Antifibrinolytic medications like tranexamic acid help prevent clot breakdown and are particularly useful for mucosal bleeding and dental procedures. Hormonal therapies, including combined oral contraceptives and hormonal IUDs, can effectively manage menorrhagia in women.
Local measures include topical agents for nosebleeds and dental bleeding. Emergency treatment may require blood transfusions, though this is rarely necessary with proper prophylactic treatment.
Prognosis
With proper diagnosis and treatment, most people with Von Willebrand disease have excellent long-term outcomes and normal life expectancy. Type 1 VWD, the mildest and most common form, often requires minimal intervention and doesn’t significantly impact daily life.
Type 2 variants have variable prognosis depending on the specific subtype, but most patients respond well to appropriate treatment. Type 3 VWD, while most severe, can be effectively managed with regular factor replacement therapy, allowing patients to lead active lives.
Early diagnosis and access to specialized care significantly improve outcomes. Patients who receive appropriate treatment before major bleeding episodes generally have better quality of life and fewer complications than those diagnosed after serious bleeding events.
Quality of life
Most people with well-managed Von Willebrand disease can participate in normal activities, including sports and exercise, with appropriate precautions. Contact sports may require special consideration and protective equipment, while activities with high bleeding risk might be avoided.
Dietary considerations include maintaining adequate iron intake to prevent anemia, especially for women with heavy periods. Regular exercise actually helps improve overall health and may positively impact bleeding symptoms.
Mental health support is important, particularly during adolescence when heavy periods can cause embarrassment and social isolation. Patient education about the condition empowers individuals to recognize bleeding patterns and seek appropriate care.
Work and school accommodations may be necessary during bleeding episodes, but most patients maintain normal productivity. Open communication with healthcare providers, employers, and teachers helps ensure appropriate support when needed.
Pregnancy and fertility
Von Willebrand disease typically doesn’t affect fertility, though heavy menstrual periods may interfere with conception timing. Von Willebrand factor levels often increase during pregnancy, potentially improving bleeding symptoms temporarily.
Pregnancy management requires specialized care with monitoring of factor levels and delivery planning. Most women can have normal vaginal deliveries, though preparation for potential bleeding complications is essential.
Genetic counseling helps couples understand inheritance risks. Each child of an affected parent has a 50% chance of inheriting the condition in dominant forms, while recessive forms require both parents to be carriers.
Postpartum bleeding risk remains elevated for several weeks after delivery, requiring continued monitoring and treatment as needed.
Children
Children with VWD often present with frequent nosebleeds, easy bruising, or excessive bleeding after dental procedures. Diagnosis can be challenging since bleeding symptoms may be attributed to normal childhood activities.
School accommodations might include access to the nurse for nosebleeds, permission to change clothes if bleeding occurs, and modifications during physical education if needed. Teachers should be informed about the condition and emergency procedures.
Preventive treatment before dental work, surgery, or certain activities may be necessary. Children should wear medical alert jewelry and families should maintain emergency care plans.
Transition to adult care typically occurs during late adolescence, with gradual transfer of self-management responsibilities from parents to the young adult.
When to see a doctor
Urgent medical attention is needed for severe bleeding that doesn’t stop with direct pressure, signs of severe anemia (weakness, dizziness, pale skin), or bleeding following surgery or dental procedures.
Routine consultation is appropriate for frequent nosebleeds, easy bruising, heavy menstrual periods lasting more than seven days, or family history of bleeding disorders. Preparation before elective surgery or dental work is essential.
Genetic counseling should be considered before pregnancy planning or when multiple family members have bleeding symptoms.
Regional context
Von Willebrand disease prevalence in the Caucasus region (Georgia, Armenia, Azerbaijan) and Eastern Mediterranean follows global patterns, though specific population studies are limited. Some isolated populations may have higher rates of certain VWD types due to founder effects.
Access to specialized coagulation testing and treatment products varies across the region. The Global Medical Journal welcomes contributions from regional hematologists and patient advocates to better understand VWD burden and treatment accessibility in these areas.
Research and clinical trials
Current research focuses on developing longer-acting treatments, improved diagnostic tests, and novel therapeutic approaches. Extended half-life von Willebrand factor concentrates are in development to reduce treatment frequency.
Gene therapy research shows promise for severe VWD, though clinical applications remain years away. Studies of non-factor therapies that enhance clot formation without replacing von Willebrand factor are ongoing.
Patients can search for relevant clinical trials at ClinicalTrials.gov using terms “von Willebrand disease” and their specific location. Participation in research studies helps advance treatment options for future patients.
Frequently asked questions
Is Von Willebrand disease the same as hemophilia?
No, while both are bleeding disorders, they affect different clotting proteins. VWD affects von Willebrand factor and typically causes mucosal bleeding, while hemophilia affects factors VIII or IX and more commonly causes joint and muscle bleeding.
Can women with VWD have children safely?
Yes, most women with VWD can have safe pregnancies and deliveries with proper medical management. Von Willebrand factor levels often increase during pregnancy, potentially improving symptoms temporarily.
Will my children inherit VWD if I have it?
In the most common autosomal dominant forms, each child has a 50% chance of inheriting the condition. However, symptoms can vary widely even within families, and many people with inherited mutations have mild or no symptoms.
Do I need to avoid all physical activities?
No, most people with VWD can participate in normal activities. However, contact sports may require special precautions, and high-risk activities might need to be avoided or modified based on individual bleeding severity.
Can VWD be cured?
Currently, there’s no cure for VWD, but it can be effectively managed with appropriate treatment. Most people with VWD live normal, active lives with proper medical care and preventive measures.
Support and resources
International organizations:
– World Federation of Hemophilia (WFH): www.wfh.org
– National Hemophilia Foundation: www.hemophilia.org
– Haemophilia Society (UK): haemophilia.org.uk
– EURORDIS (Rare Diseases Europe): www.eurordis.org
– Orphanet: www.orpha.net
– National Organization for Rare Disorders (NORD): rarediseases.org
Related conditions
Hemophilia A, Hemophilia B, Bernard-Soulier syndrome, Glanzmann thrombasthenia, Platelet function disorders
Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, relevant guidelines. Informational only; not medical advice. CC BY 4.0.
Cite this page
GMJ News Desk. “Von Willebrand disease.” GMJ News — Georgian Medical Journal, 2 June 2026. https://news.gmj.ge/condition/von-willebrand-disease/
Licensed under CC BY 4.0. Free to share with attribution to GMJ News.Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.
Was this article helpful?